8-K: PURE Bioscience Reports Q3 2026 Results, CEO to Retire

PURE Bioscience announced fiscal third quarter 2026 financial results, showing increased net product sales and a reduced net loss for the nine-month period, alongside a significant leadership transition.

Summary

• PURE Bioscience reported net product sales of $506,000 for the fiscal third quarter ended April 30, 2026, an increase from $489,000 in the prior year's quarter.
• The net loss for the third quarter was $624,000, compared to $580,000 in the same period last year.
• For the nine months ended April 30, 2026, net product sales increased to $1,656,000 from $1,435,000 in the prior year.
• The net loss for the nine-month period improved to $1,873,000 from $2,067,000 in the prior year.
• CEO Robert F. Bartlett announced his retirement effective July 31, 2026, and President Jeff Kitchell will assume the CEO role on August 1, 2026.
• Bernard Blotner will be leaving the Board of Directors.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, with positive revenue trends and improved year-to-date net loss offset by an increased quarterly net loss and significant leadership changes.

Positives

• Net product sales increased by $17,000 to $506,000 in the fiscal third quarter ended April 30, 2026, driven by higher sales across the distribution network.
• Net product sales for the nine months ended April 30, 2026, increased by $221,000 to $1,656,000, attributed to higher sales across the end-user network.
• Net loss for the nine months ended April 30, 2026, decreased to $1,873,000 from $2,067,000 in the prior year.
• Net loss, excluding share-based compensation, for the nine months ended April 30, 2026, decreased to $1,726,000 from $1,950,000.
• PURE Clean has begun commercial adoption with national food brands, generating initial sales.
• Continued growth in the transportation sector driven by increased adoption of trailer treatment programs and new product introductions like PURE Fleet Wash.
• Management states that momentum is building due to deliberate actions, expanding reach, strengthening partnerships, and positioning PURE for sustainable long-term growth.

Negatives

• Net loss for the fiscal third quarter ended April 30, 2026, increased to $624,000 from $580,000 in the prior year's quarter.
• Net loss, excluding share-based compensation, for the fiscal third quarter ended April 30, 2026, increased to $569,000 from $547,000 in the prior year's quarter.
• Total liabilities increased to $7,397,000 as of April 30, 2026, from $6,174,000 as of July 31, 2025.
• Stockholders' deficiency increased to $(5,839,000) as of April 30, 2026, from $(5,116,000) as of July 31, 2025.

Risks

• The Company's failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans.
• Acceptance of PURE products in the marketplace, including the ability to convert evaluations into customer orders and for customers to continue placing orders.
• The Company's ability to maintain relationships with its partners and other counterparties.
• The Company's ability to generate sufficient revenues and reduce operating expenses to reach profitability.
• The Company's ability to raise the funding required to support continued operations and business plan implementation.
• The ability to develop effective new products and receive required regulatory approvals.
• Competitive factors, including customer acceptance of SDC-based products that may be more expensive than existing treatment chemicals.
• Dependence upon third-party vendors for manufacturing.

Future Outlook

The company is focused on executing its strategy for sustainable long-term growth, driven by expanding reach, strengthening partnerships, and continued R&D for innovative solutions using its proprietary SDC technology. New products like PURE Clean are seeing commercial adoption, and advancements are being made in food safety platforms and transportation sector offerings.

Management Comments

• "Our fiscal year-over-year sales have continued to grow while reducing operating expenses. We have continued to develop our technology, introducing new products such as PURE Clean, and to expand into new industries, including dairy, through our game-changing membrane treatment program delivered by our distribution partners. Our ongoing R&D work is driven by industry demand for more effective and safer solutions and by our commitment to meeting that demand with innovative solutions using our proprietary SDC technology."
• "The momentum we're building today is the result of deliberate actions our team has been taking. While there is still work to do, we are expanding our reach, strengthening our partnerships, and positioning PURE for sustainable long-term growth. We believe the future is bright and remain focused on executing our strategy."
• "It has been a privilege to serve PURE Bioscience and to lead such an outstanding and talented team who are all dedicated to seeing the success of this Company. I wish I were a younger man and could give more of my life to this wonderful organization."
• "While we are deeply saddened to see him step down, we are incredibly grateful for his dedication and the significant impact he had during his tenure. During his time on the Board, Mr. Blotner played a pivotal role in guiding the organizations strategic expansion."
• "It has been an honor to serve on the Board of PURE. While I must step down to focus on my health, I am incredibly proud of what has been accomplished and remain a strong supporter of the organizations mission."

Industry Context

StockSavvy.ai notes that PURE Bioscience's focus on SDC antimicrobial technology aligns with a broader industry trend towards safer, non-toxic solutions in food safety and industrial applications. The company's expansion into new sectors like dairy and its continued development in transportation reflect efforts to diversify and capture market share in areas demanding advanced hygiene and sanitation.

Management Changes

Related Party Transactions

• Convertible notes payable to related parties are listed as current ($2,754,000) and non-current ($3,743,000) liabilities.

Stakeholder Impact

• Shareholders: The retirement of a long-serving CEO and the appointment of a new CEO may introduce uncertainty, though the company aims for continued growth. Stock performance could be influenced by the transition and future financial results.
• Employees: Leadership changes can impact company culture and strategic direction. The focus on growth and new product adoption suggests continued operational activity.
• Customers: Continued development and adoption of products like PURE Clean and PURE Fleet Wash indicate ongoing commitment to serving customer needs for effective and safe solutions.
• Suppliers: The company's reliance on third-party vendors for manufacturing remains a factor.

Next Steps

• Jeff Kitchell to assume CEO role on August 1, 2026.
• AJ Bogan to present on SDC technology for membrane treatment at the Membrane Technology Forum on June 16, 2026.
• Continued commercial adoption and expansion of PURE Clean.
• Advancement of food safety platform through automation, spiral freezer solutions, and drain sanitation programs.
• Continued growth and expansion in the transportation sector with PURE Fleet Wash.

Key Dates

Recommendation

The company shows positive trends in sales growth and improved year-to-date net loss, alongside strategic product development. However, the increased quarterly net loss, growing liabilities, and significant management transition (CEO retirement) introduce a degree of uncertainty that warrants a 'hold' recommendation pending further clarity on the new leadership's execution and financial performance stabilization.

Keywords

PURE Bioscience, SDC antimicrobial, financial results, Q3 2026, CEO retirement, food safety, transportation sector, antimicrobial technology